...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-alpha in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.
【24h】

Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-alpha in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease.

机译:Ca(2 +)/钙调蛋白依赖性蛋白激酶II-alpha在轻度认知障碍和阿尔茨海默氏病患者海马中的磷酸化失调。

获取原文
获取原文并翻译 | 示例

摘要

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder and the most prevalent senile dementia. The early symptom of memory dysfunction involves synaptic loss, thought to be mediated by soluble amyloid-beta (Abeta) oligomers. These aggregate species target excitatory synapses and their levels correlate with disease severity. Studies in cell culture and rodents have shown that oligomers increase intracellular calcium (Ca(2+)), impairing synaptic plasticity. Yet, the molecular mechanism mediating Abeta oligomers' toxicity in the aged brain remains unclear. Here, we apply quantitative immunofluorescence in human brain tissue from clinically diagnosed mild cognitive impaired (MCI) and AD patients to investigate the distribution of phosphorylated (active) Ca(2+) /calmodulin-dependent protein kinase-alpha (p(Thr286)CaMKII), a critical enzyme for activity-dependent synaptic remodeling associated with cognitive function. We show that p(Thr286)CaMKII immunoreactivity is redistributed from dendritic arborizations to neural perikarya of both MCI and AD hippocampi. This finding correlates with cognitive assessment scores, suggesting that it may be a molecular read-out of the functional deficits in early AD. Treatment with oligomeric Abeta replicated the observed phenotype in mice and resulted in a loss of p(Thr286)CaMKII from synaptic spines of primary hippocampal neurons. Both outcomes were prevented by inhibiting the phosphatase calcineurin (CaN). Collectively, our results support a model in which the synaptotoxicity of Abeta oligomers in human brain involves the CaN-dependent subcellular redistribution of p(Thr286)CaMKII. Therapies designed to normalize the homeostatic imbalance of neuronal phosphatases and downstream dephosphorylation of synaptic p(Thr286)CaMKII should be considered to prevent and treat early AD.
机译:阿尔茨海默氏病(AD)是一种进行性神经退行性疾病和最普遍的老年性痴呆。记忆功能障碍的早期症状涉及突触丧失,据认为是由可溶性淀粉样β(Abeta)低聚物介导的。这些聚集的物种靶向兴奋性突触,其水平与疾病的严重程度相关。在细胞培养和啮齿动物中的研究表明,低聚物会增加细胞内钙(Ca(2+)),损害突触可塑性。但是,尚不清楚在老年大脑中介导Abeta低聚物毒性的分子机制。在这里,我们从临床诊断为轻度认知障碍(MCI)和AD患者的人脑组织中应用定量免疫荧光,以研究磷酸化(活性)Ca(2 +)/钙调蛋白依赖性蛋白激酶-α(p(Thr286)CaMKII ),一种与认知功能相关的活动依赖性突触重塑的关键酶。我们显示p(Thr286)CaMKII免疫反应性是从树突状树突重新分布到MCI和AD海马的神经周围核。该发现与认知评估得分相关,表明它可能是早期AD功能缺陷的分子读数。用寡聚Abeta处理可在小鼠中复制观察到的表型,并导致海马神经元突触棘失去p(Thr286)CaMKII。抑制磷酸酶钙调磷酸酶(CaN)可防止两种结果。总的来说,我们的结果支持一种模型,其中人脑中Abeta低聚物的突触毒性涉及p(Thr286)CaMKII的CaN依赖性亚细胞再分布。应该考虑采用旨在使神经元磷酸酶体内稳态失衡和突触p(Thr286)CaMKII下游去磷酸化正常化的疗法来预防和治疗早期AD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号